MCID: KHN001
MIFTS: 45

Kuhnt-Junius Degeneration

Categories: Eye diseases

Aliases & Classifications for Kuhnt-Junius Degeneration

MalaCards integrated aliases for Kuhnt-Junius Degeneration:

Name: Kuhnt-Junius Degeneration 12 15
Neovascular Age-Related Macular Degeneration 12 15
Exudative Senile Macular Degeneration of Retina 12
Exudative Age-Related Macular Degeneration 72
Wet Senile Macular Retinal Degeneration 12
Senile Macular Degeneration, Wet 12
Exudative Macular Degeneration 72

Classifications:



External Ids:

Disease Ontology 12 DOID:10873
ICD9CM 35 362.52
SNOMED-CT 68 11290001 16018000
ICD10 33 H35.32
UMLS 72 C0271084 C2237660

Summaries for Kuhnt-Junius Degeneration

MalaCards based summary : Kuhnt-Junius Degeneration, also known as neovascular age-related macular degeneration, is related to yemenite deaf-blind hypopigmentation syndrome and microvascular complications of diabetes 5. An important gene associated with Kuhnt-Junius Degeneration is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Focal Adhesion and MAPK signaling pathway. The drugs Verteporfin and Indomethacin have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotype is vision/eye.

Related Diseases for Kuhnt-Junius Degeneration

Diseases related to Kuhnt-Junius Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 136)
# Related Disease Score Top Affiliating Genes
1 yemenite deaf-blind hypopigmentation syndrome 32.0 VEGFA CFH
2 microvascular complications of diabetes 5 31.6 VEGFA PGF KDR
3 central serous chorioretinopathy 31.3 CFH ARMS2
4 neovascular glaucoma 30.9 VEGFA PGF
5 retinal disease 30.8 CFH CFB ARMS2
6 retinal vascular disease 30.7 VEGFA PGF KDR
7 leukostasis 30.6 VEGFA KDR
8 choroiditis 30.3 CFH CFB ARMS2
9 macular degeneration, age-related, 1 26.1 VEGFB VEGFA SKIV2L SHROOM3 PGF KDR
10 endophthalmitis 10.9
11 macular retinal edema 10.9
12 retinal detachment 10.8
13 periodontal ehlers-danlos syndrome 10.8
14 eye disease 10.7
15 triiodothyronine receptor auxiliary protein 10.6
16 cataract 10.6
17 vitreous detachment 10.6
18 macular degeneration, age-related, 12 10.6
19 hydrops, lactic acidosis, and sideroblastic anemia 10.6
20 uveitis 10.6
21 48,xyyy 10.6
22 47,xyy 10.6
23 macular holes 10.5
24 scotoma 10.5
25 ocular hypertension 10.5
26 hypercholesterolemia, familial, 1 10.4
27 myopia 10.4
28 vascular disease 10.4
29 diabetic macular edema 10.4
30 cytokine deficiency 10.4
31 cancer-associated retinopathy 10.4 VEGFA PGF
32 histoplasmosis 10.4 CFH ARMS2
33 retinal vascular occlusion 10.4 VEGFA PGF
34 microvascular complications of diabetes 1 10.4
35 microvascular complications of diabetes 2 10.4
36 retinal vein occlusion 10.4
37 optic nerve disease 10.4
38 pulmonary embolism 10.4
39 charles bonnet syndrome 10.4
40 dowling-degos disease 1 10.3
41 vitreoretinopathy, neovascular inflammatory 10.3
42 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
43 pars planitis 10.3
44 angioid streaks 10.3
45 intraocular pressure quantitative trait locus 10.3
46 macular degeneration, age-related, 6 10.3
47 nasopharyngitis 10.3
48 intracranial aneurysm 10.3
49 thrombophilia 10.3
50 iridocyclitis 10.3

Graphical network of the top 20 diseases related to Kuhnt-Junius Degeneration:



Diseases related to Kuhnt-Junius Degeneration

Symptoms & Phenotypes for Kuhnt-Junius Degeneration

MGI Mouse Phenotypes related to Kuhnt-Junius Degeneration:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.1 CFH KDR PGF VEGFA VEGFB VLDLR

Drugs & Therapeutics for Kuhnt-Junius Degeneration

Drugs for Kuhnt-Junius Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 192)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verteporfin Approved, Investigational Phase 4 129497-78-5
2
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
5
Bevacizumab Approved, Investigational Phase 4 216974-75-3
6
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
7 Photosensitizing Agents Phase 4
8 Dermatologic Agents Phase 4
9 Omega 3 Fatty Acid Phase 4
10 Cyclooxygenase Inhibitors Phase 4
11 Tocolytic Agents Phase 4
12 Ketorolac Tromethamine Phase 4
13 Pyranoprofen Phase 4
14 Autoantibodies Phase 4
15 Analgesics Phase 4
16 Analgesics, Non-Narcotic Phase 4
17 Peripheral Nervous System Agents Phase 4
18 Anti-Inflammatory Agents, Non-Steroidal Phase 4
19 Antirheumatic Agents Phase 4
20 Gastrointestinal Agents Phase 4
21 Cathartics Phase 4
22 Carboxymethylcellulose Sodium Phase 4
23 Laxatives Phase 4
24 Pharmaceutical Solutions Phase 4
25 Antineoplastic Agents, Immunological Phase 4
26
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
27
tannic acid Approved Phase 3 1401-55-4
28
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
29
Dorzolamide Approved Phase 2, Phase 3 120279-96-1 3154 5284549
30
Povidone Approved Phase 3 9003-39-8
31
Iodine Approved, Investigational Phase 3 7553-56-2 807
32
Povidone-iodine Approved Phase 3 25655-41-8
33
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
34
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
35
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
36
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
37 Anecortave Investigational Phase 3 10184-70-0
38 Hormone Antagonists Phase 3
39 triamcinolone acetonide Phase 3
40 Triamcinolone diacetate Phase 3
41 Anti-Inflammatory Agents Phase 3
42 Triamcinolone hexacetonide Phase 3
43 Hormones Phase 3
44 glucocorticoids Phase 3
45 Immunologic Factors Phase 3
46 Immunosuppressive Agents Phase 3
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
48 Alfalfa Phase 3
49 Anti-Bacterial Agents Phase 3
50 Antibiotics, Antitubercular Phase 3

Interventional clinical trials:

(show top 50) (show all 368)
# Name Status NCT ID Phase Drugs
1 Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations Unknown status NCT01213667 Phase 4 Ranibizumab
2 Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Unknown status NCT02810808 Phase 4 Ranibizumab
3 A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
4 Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910) Unknown status NCT01961414 Phase 4 Aflibercept
5 A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD). Unknown status NCT01918878 Phase 4 Aflibercept (EYLEA)
6 Efficacy of Ranibizumab (Lucentis) in Combination With Photodynamic Therapy for Neovascular Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab;Ranibizumab;Ranibizumab
7 Clinical and Genetic Assessment of Treatment Response in Patients With Age-related Macular Degeneration Using Intravitreal Aflibercept Injection Unknown status NCT02689518 Phase 4 Intravitreal aflibercept injection
8 A Multicenter Study Comparing Efficacy and Safety of " Treat-and-Extend" Regimen Versus PRN Regimen of Conbercept in Neovascular Age-related Macular Degeneration Unknown status NCT02802657 Phase 4 Conbercept
9 A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions Completed NCT00324116 Phase 4 pegaptanib sodium (Macugen)
10 A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study) Completed NCT01617148 Phase 4 Aflibercept
11 LUCAS. A Randomized, Prospective, Multicenter Study Comparing the Effect of Intravitreal Injection of Bevacizumab to Ranibizumab When Given to Patients With Neovascular Age-related Macular Degeneration Completed NCT01127360 Phase 4 Bevacizumab;Ranibizumab
12 Efficacy of Intravitreal Aflibercept Monotherapy for Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial Completed NCT03169660 Phase 4 Vascular endothelial growth factor trap-eye
13 Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration. Completed NCT02321839 Phase 4 Intraviteal Ranibizumab 0.5mg
14 Size Progression of Non-Exudative Age-Related Macular Degeneration After Cataract Surgery Completed NCT01165801 Phase 4
15 A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment naïve Neovascular Age-related Macular Degeneration (nAMD) Patients Completed NCT01988662 Phase 4
16 Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept in Patients With Exudative Age-related Macular Degeneration Completed NCT02125864 Phase 4 Aflibercept
17 FUSION Regimen: A Disease Activity Guided Treatment Algorithm With Ranibizumab in naïve Subjects With Exudative Age-related Macular Degeneration Completed NCT01500915 Phase 4 Ranibizumab
18 Phase IV Study to Evaluate the Efficacy of Aflibercept in Subjects With Neovascular Age-related Macular Degeneration (wAMD), Without Optimal Response to Repeated Monthly Intravitreal Injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy. Completed NCT01896284 Phase 4 0.5mg aflibercept
19 A 24-month, Randomized, Double-masked, Controlled, Multicenter Study Evaluating the Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With Neovascular Age Related Macular Degeneration (AMD) Completed NCT01775124 Phase 4 Ranibizumab
20 Prospective Randomized Controlled Trial of Combination Ranibizumab and Indomethacin for Exudative Age-Related Macular Degeneration Completed NCT03261635 Phase 4 Ranibizumab Injection;Indomethacin
21 A Randomised Controlled Trial of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration Completed NCT02060604 Phase 4 Ketorolac + Ranibizumab;Ranibizumab
22 An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
23 A Prospective, Interventional Case Series, Effect of Lucentis on Indocyanine Angiographic Changes in Patients With Wet Age-related Macular Degeneration Completed NCT01810042 Phase 4 ranibizumab
24 Clinical Research of Photodynamic Therapy for Exudative Age-related Macular Degeneration Accompanied With Polypoidal Choroidal Vasculopathy Completed NCT00331435 Phase 4
25 An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
26 A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration Completed NCT02142296 Phase 4 Eylea
27 Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES) Completed NCT02581891 Phase 4 Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321);Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
28 Treatment of Exudative Age-Related Macular Degeneration With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3: A Randomized Trial Completed NCT03355638 Phase 4 Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation
29 Single or Combined Protocols for the Treatment of Patients With Neovascular Age-related Macular Degeneration: Compliance, Risk/Benefit and Cost/Benefit Ratios Completed NCT03552770 Phase 4 Bevacizumab
30 Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®) (2mg) Over a 12-week Period for Patients Suffering From Neovascular Age-related Macular Degeneration (AMD) French SD OCT in wAMD Completed NCT02246829 Phase 4
31 A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Completed NCT01958918 Phase 4 Ranibizumab;Aflibercept
32 A Randomized, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Repeated Doses of Intravitreal Aflibercept With Variable Treatment Intervals in Japanese Subjects With Neovascular Age-related Macular Degeneration Completed NCT02305238 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
33 A Randomized, Single-blinded, Multicenter, Phase IV Study to Compare Systemic VEGF Protein Dynamics Following Monthly Intravitreal Injections of 0.5 mg Ranibizumab Versus 2 mg Aflibercept Until Study Week 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration Completed NCT02257632 Phase 4 Ranibizumab 0.5 mg;Aflibercept 2 mg
34 A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg. Completed NCT02161575 Phase 4 Ranibizumab
35 Efficacy of Fixed Monthly Dosing of Lucentis® (Ranibizumab) on Subretinal Fluid (SRF) Associated With Persistent Pigment Epithelial Detachment (PED) in Neovascular Age-related Macular Degeneration (AMD): A Pilot Study Completed NCT02944227 Phase 4 Lucentis
36 A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study). Completed NCT01863199 Phase 4 Lucentis (Treat and extend);Lucentis every 4 weeks;Lucentis every 12 weeks
37 An Exploratory Single Site, Open Label, Randomized, Controlled Study to Evaluate Plasma Vascular Endothelial Growth Factor Levels After Intravitreal Injection of Ranibizumab (Lucentis) and Conbercept (Langmu) for nAMD Completed NCT02577107 Phase 4 ranibizumab;Conbercept
38 A Prospective Pilot Study of Reduced Fluence Photodynamic Therapy With Visudyne® (Verteporfin) in Combination With Lucentis™ (Ranibizumab) for the Treatment of Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
39 VEGF and HTRA1 DNA Polymorphisms in Neovascular AMD Pathogenesis and Response to Lucentis Completed NCT01464723 Phase 4 Ranibizumab
40 AflibercepT for Subjects Who Are Incomplete Responders to mUltiple Intravitreal Injections of Ranibizumab, Anti-VegF (The TURF Study) Completed NCT01543568 Phase 4 aflibercept 2.0 mg
41 Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial Completed NCT02843490 Phase 4 Ranibizumab
42 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
43 A Prospective Randomized Controlled Multicentre Trial Comparing Half-dose Photodynamic Therapy (PDT) With High-density Subthreshold Micropulse Laser Treatment in Patients With Chronic Central Serous Chorioretinopathy (CSC) Completed NCT01797861 Phase 4
44 A Phase IV OpenLabelled Prospective Pilot Study of Intravitreal Macugen (Pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME Study) Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
45 Intraocular Cytokine Changes in Recurrence of Polypoidal Choroidal Vasculopathy Recruiting NCT02976194 Phase 4 ranibizumab
46 The IAI-OCTA Study or; Microvascular Structure and Morphology of Neovascular Membranes in Age Related Macular Degeneration (AMD) After Intravitreal Aflibercept Injection (IAI) Therapy Using OCT-Angiography Analysis Recruiting NCT03022292 Phase 4 Aflibercept Ophthalmic
47 Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pressure Patching: A Prospective, Randomized, Placebo Controlled Trial Enrolling by invitation NCT03918590 Phase 4 nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX);Theratears tear drop, (Akron, Ann 111 Arbor, MI)
48 PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept Not yet recruiting NCT02681783 Phase 4 aflibercept
49 Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Aflibercept Treatment: The COVARIANT Study Not yet recruiting NCT03056079 Phase 4 Intravitreal aflibercept
50 Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Ranibizumab Treatment: The COVERT Study Not yet recruiting NCT03056092 Phase 4 Intravitreal ranibizumab

Search NIH Clinical Center for Kuhnt-Junius Degeneration

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aflibercept
Pegaptanib
Ranibizumab

Genetic Tests for Kuhnt-Junius Degeneration

Anatomical Context for Kuhnt-Junius Degeneration

MalaCards organs/tissues related to Kuhnt-Junius Degeneration:

41
Eye, Endothelial, Retina, Testes, Bone, Bone Marrow, Monocytes

Publications for Kuhnt-Junius Degeneration

Articles related to Kuhnt-Junius Degeneration:

(show top 50) (show all 2522)
# Title Authors PMID Year
1
The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. 38
30797883 2019
2
Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update. 38
31309853 2019
3
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. 38
31256237 2019
4
Short-term effect on the ocular circulation induced by unilateral intravitreal injection of aflibercept in age-related maculopathy. 38
30916896 2019
5
IMPROVED DETECTION AND DIAGNOSIS OF POLYPOIDAL CHOROIDAL VASCULOPATHY USING A COMBINATION OF OPTICAL COHERENCE TOMOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. 38
29927796 2019
6
Angiotensin II and aldosterone in retinal vasculopathy and inflammation. 38
31425690 2019
7
Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project. 38
30862501 2019
8
Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. 38
31281103 2019
9
Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration. 38
31144055 2019
10
Long-Term Management of Neovascular Age-Related Macular Degeneration: To Suspend or Not to Suspend? 38
31383395 2019
11
Neovascularization in Fellow Eye of Unilateral Neovascular Age-Related Macular Degeneration According to Different Drusen Types. 38
31377285 2019
12
Reliability of colour perimetry to assess macular pigment optical density in age-related macular degeneration. 38
31422700 2019
13
Trainee-led versus specialist-led management of neovascular age-related macular degeneration: a registry-based study. 38
30385435 2019
14
Retinal metabolic and structural alterations in response to aflibercept treatment in neovascular age-related macular degeneration. 38
30549221 2019
15
Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration. 38
30740921 2019
16
Colour contrast sensitivity in eyes at high risk of neovascular age-related macular degeneration. 38
31411062 2019
17
Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up. 38
30909756 2019
18
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. 38
30946888 2019
19
Identification and characterization of a novel promoter variant in placental growth factor for neovascular age-related macular degeneration. 38
31377148 2019
20
An in vitro Assessment of Thermo-Reversible Gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration. 38
31399890 2019
21
Volumetric Analysis of Vascularized Serous Pigment Epithelial Detachment Progression in Neovascular Age-Related Macular Degeneration Using Optical Coherence Tomography Angiography. 38
31369033 2019
22
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. 38
31383649 2019
23
Hypertensive disorders of pregnancy increase the risk of developing neovascular age-related macular degeneration in later life. 38
30977693 2019
24
[Baseline diagnostics and initial treatment decision for anti-vascular endothelial growth factor treatment in retinal diseases : Comparison between results by study physician and reading centers (ORCA/OCEAN study)]. 38
30367231 2019
25
One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation. 38
31401554 2019
26
REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study. 38
31385918 2019
27
The Placental Growth Factor Pathway and Its Potential Role in Macular Degenerative Disease. 38
31055948 2019
28
Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) in a Norwegian population of patients with neovascular age-related macular degeneration compared to a control population. 38
31412873 2019
29
Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration. 38
30511374 2019
30
CORRELATION OF SUBRETINAL HYPERREFLECTIVE MATERIAL MORPHOLOGY AND VISUAL ACUITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. 38
31305505 2019
31
[Patient-Reported Treatment Satisfaction with Stereotactic Radiotherapy in Neovascular Age-Related Macular Degeneration]. 38
28837976 2019
32
Early local activation of complement in aqueous humour of patients with age-related macular degeneration. 38
31267090 2019
33
Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration. 38
30813810 2019
34
Choroidal cleft simulating choroidal caverns in neovascular age-related macular degeneration. 38
31353948 2019
35
Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration. 38
31366903 2019
36
Innovative therapies for neovascular age-related macular degeneration. 38
31298960 2019
37
Oral Tyrosine Kinase Inhibitors for Neovascular Age-Related Macular Degeneration. 38
31046112 2019
38
Circulating endothelial and progenitor cells in age-related macular degeneration. 38
31328962 2019
39
Review of neovascular age-related macular degeneration treatment options. 38
31419088 2019
40
Angiographic Subtypes of Neovascular Age-related Macular Degeneration in Korean: A New Diagnostic Challenge. 38
31273295 2019
41
A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. 38
31350409 2019
42
Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization. 38
31374338 2019
43
[Change in Therapy of Neovascular Age-Related Macular Degeneration, Diabetic Maculopathy and Macular Edema after Retinal Vein Occlusion]. 38
29025174 2019
44
Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. 38
31302628 2019
45
Dietary Habits, Fatty Acids and Carotenoid Levels Are Associated with Neovascular Age-Related Macular Degeneration in Chinese. 38
31349710 2019
46
CONBERCEPT IN PATIENTS WITH TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN REAL-LIFE SETTING IN CHINA. 38
29547454 2019
47
Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. 38
31119425 2019
48
Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. 38
31282617 2019
49
How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview. 38
31102206 2019
50
The Value of Prior Response to Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration: A HARBOR Subanalysis. 38
31416763 2019

Variations for Kuhnt-Junius Degeneration

Expression for Kuhnt-Junius Degeneration

Search GEO for disease gene expression data for Kuhnt-Junius Degeneration.

Pathways for Kuhnt-Junius Degeneration

Pathways related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 VEGFB VEGFA PGF KDR
2 12.4 VEGFB VEGFA PGF KDR
3
Show member pathways
12.31 VEGFB VEGFA PGF KDR
4
Show member pathways
12.15 VEGFB VEGFA PGF KDR
5
Show member pathways
12.09 VEGFB VEGFA KDR
6
Show member pathways
11.93 VEGFB VEGFA PGF KDR
7
Show member pathways
11.91 VEGFB VEGFA KDR
8
Show member pathways
11.15 VEGFA KDR
9 11.04 VEGFA KDR
10
Show member pathways
10.89 VEGFB VEGFA PGF KDR
11 10.84 VEGFA KDR
12 10.77 VEGFB VEGFA KDR
13 10.73 VEGFB VEGFA KDR
14 10.11 VEGFB VEGFA

GO Terms for Kuhnt-Junius Degeneration

Cellular components related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 VLDLR VEGFB VEGFA PGF CFH CFB
2 extracellular region GO:0005576 9.23 VEGFB VEGFA PGF KDR CFHR4 CFHR2

Biological processes related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.83 VEGFB VEGFA PGF KDR
2 positive regulation of protein phosphorylation GO:0001934 9.76 VEGFB VEGFA PGF KDR
3 response to hypoxia GO:0001666 9.75 VEGFB VEGFA PGF
4 regulation of cell shape GO:0008360 9.73 VEGFA SHROOM3 KDR
5 positive regulation of angiogenesis GO:0045766 9.73 VEGFB VEGFA PGF KDR
6 positive regulation of cell division GO:0051781 9.67 VEGFB VEGFA PGF
7 regulation of complement activation GO:0030449 9.67 CFHR4 CFHR2 CFH CFB
8 positive chemotaxis GO:0050918 9.65 VEGFB VEGFA PGF
9 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.6 VEGFA KDR
10 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.59 VEGFA KDR
11 positive regulation of focal adhesion assembly GO:0051894 9.58 VEGFA KDR
12 sprouting angiogenesis GO:0002040 9.58 VEGFB VEGFA PGF
13 cell migration involved in sprouting angiogenesis GO:0002042 9.57 VEGFA KDR
14 positive regulation of endothelial cell proliferation GO:0001938 9.56 VEGFB VEGFA PGF KDR
15 complement activation, alternative pathway GO:0006957 9.55 CFH CFB
16 positive regulation of positive chemotaxis GO:0050927 9.54 VEGFA KDR
17 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.51 VEGFA KDR
18 induction of positive chemotaxis GO:0050930 9.5 VEGFB VEGFA PGF
19 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.46 VEGFB VEGFA PGF KDR
20 positive regulation of mast cell chemotaxis GO:0060754 9.13 VEGFB VEGFA PGF
21 vascular endothelial growth factor signaling pathway GO:0038084 8.92 VEGFB VEGFA PGF KDR

Molecular functions related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.67 VEGFB VEGFA PGF CFHR2
2 growth factor activity GO:0008083 9.5 VEGFB VEGFA PGF
3 heparin binding GO:0008201 9.46 VEGFB VEGFA PGF CFH
4 chemoattractant activity GO:0042056 9.13 VEGFB VEGFA PGF
5 vascular endothelial growth factor receptor 2 binding GO:0043184 8.96 VEGFA
6 vascular endothelial growth factor receptor 1 binding GO:0043183 8.62 VEGFB VEGFA

Sources for Kuhnt-Junius Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....